stockportfolio.pro
Stocks / SRRK vs XENE
SRRK vs XENE
Scholar Rock Holding Corporation and Xenon Pharmaceuticals Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Scholar Rock Holding Corporation (SRRK) | Xenon Pharmaceuticals Inc. (XENE) | |
|---|---|---|
| Market cap | $5.3B | $5.0B |
| Revenue (latest FY) | $0 | $7.50M |
| Net income (latest FY) | $-377.94M | $-345.91M |
| Revenue growth (5y CAGR) | — | -25.3% |
| Net margin | — | -4612.1% |
| Return on equity | -154.0% | -59.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open SRRK — free Open XENE — freeFrequently asked questions
Which is bigger, SRRK or XENE?
Scholar Rock Holding Corporation is larger by market capitalization — $5.3B versus $5.0B.
Which grows faster, SRRK or XENE?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.